EUCTR2013-004562-33-IT进行中（未招募）1 期
PHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF A BIO-RIASSORBABLE SUBCUTANEOUS IMPLANT OF AFAMELANOTIDE IN HAILEY-HAILEY DISEASE (HHD) PATIENTS
ISTITUTI FISIOTERAPICI OSPITALIERI0 个研究点目标入组 10 人开始时间: 2013年11月18日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •MALE AND FEMALE WITH A CLINICAL/HISTOLOGICAL/GENETIC DIAGNOSIS OF HHD
- •AN AREA INDEX SCORE >2
- •AGE FROM 18 TO 80 YEARS
- •SIGNED CONSENT FORM
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •ALLERGY TO AFAMELANOTIDE
- •HISTORY OF MELANOMA, BOWEN DISEASE, SQUAMOUS CELL CARCINOMA
- •NOT USE OF CONTRACTCEPTIVE
研究者
相似试验
进行中（未招募）
1 期
A PHASE II STUDY TO ASSESS EFFICACY AND SAFETY OF PIOGLITAZONE (ACTOS®) AS ADD-ON THERAPY TO IMATINIB MESYLATE (GLEEVEC®) IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN MAJOR MOLECULAR RESPONSE (MMR). - ACTIMchronic phase chronic myelogenous leukaemia (CP-CML) patients in major molecular response.EUCTR2009-011675-79-FRCH-Versailles50
已完成
不适用
Phase II Evaluation of the Efficacy and Safety of Intravenous Estramustine Phosphate in Patients with Measurable Metastatic Cancer of Hormone Refractory Prostate.PER-034-00PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,
招募中
2 期
A PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF GLOFITAMAB IN COMBINATION WITH RITUXIMAB (R) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN CIRCULATING TUMOR (ct)DNA HIGH-RISK PATIENTS WITH UNTREATED DIFFUSE LARGE B-CELL LYMPHOMAlymph node cancer10025320B-cell lymphomaNL-OMON56027Roche Nederland B.V.2
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination with Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating tumor (ct)DNA High-Risk Patients with Untreated Diffuse Large B-Cell LymphomaDiffuse Large B-Cell LymphomaMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001647-28-NLF.Hoffmann-La Roche Ltd40
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination with Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating tumor (ct)DNA High-Risk Patients with Untreated Diffuse Large B-Cell LymphomaDiffuse Large B-Cell LymphomaMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001647-28-PLF.Hoffmann-La Roche Ltd40